Regulatory effects of microRNA‑184 on osteosarcoma via the Wnt/β‑catenin signaling pathway

Du,Zhenguang; Li,Fusheng; Wang,Liangliang; Huang,Hai; Xu,Shaonian

doi:10.3892/mmr.2018.9184

Regulatory effects of microRNA‑184 on osteosarcoma via the Wnt/β‑catenin signaling pathway

Authors:
- Zhenguang Du
- Fusheng Li
- Liangliang Wang
- Hai Huang
- Shaonian Xu
View Affiliations

Affiliations: Department of Orthopedics, The People's Hospital of Liaoning, Shenyang, Liaoning 110016, P.R. China
Published online on: June 18, 2018 https://doi.org/10.3892/mmr.2018.9184
Pages: 1917-1924
Copyright: © Du et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the role of microRNA (miRNA/miR)‑184 in osteosarcoma growth, development and metastasis, and the effects of miRNA‑184 on the proliferation, invasion and metastasis of osteosarcoma cells and associated mechanisms. In vitro, miR‑184 was transfected into U‑2OS cells and 143B cells. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was used to detect the expression of miR‑184. MTT was utilized to detect cell proliferation. A Transwell assay was applied to detect cell invasiveness. In vivo, an osteosarcoma tibial orthotopic metastatic tumor model was established, and western blotting and RT‑qPCR were used to detect the expression of Wnt and β‑catenin. Following the overexpression of miR‑184, the proliferation and cell invasion ability were significantly increased in U‑2OS and 143B cells. Following inhibition of miR‑184, cell proliferation and cell invasion ability were significantly decreased. In nude mice, tumor volume significantly increased following overexpression of miR‑184, and Wnt and phosphorylated β‑catenin levels were significantly increased. Following miR‑184 inhibition, tumor volume was significantly decreased, and Wnt and phosphorylated β‑catenin levels were significantly decreased. The results of the present study indicated that the Wnt/β‑catenin signaling pathway serves a key function in the mechanism of osteosarcoma. Inhibition of miRNA‑184 may reduce tumor volume of osteosarcoma via regulation of the Wnt/β‑catenin signaling pathway and may provide a novel strategy for the future diagnosis and treatment of osteosarcoma.

View Figures

View References

1	Unni KK: Osteosarcoma of bone. J Orthop Sci. 3:287–294. 1998. View Article : Google Scholar : PubMed/NCBI
2	Longhi A, Ferrari S, Bacci G and Specchia S: Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer Drugs. 18:737–744. 2007. View Article : Google Scholar : PubMed/NCBI
3	Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, et al: Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol. 26:633–638. 2008. View Article : Google Scholar : PubMed/NCBI
4	Hameed M and Dorfman H: Primary malignant bone tumors-recent developments. Semin Diagn Pathol. 28:86–101. 2011. View Article : Google Scholar : PubMed/NCBI
5	Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
6	Diao C, Xi Y and Xiao T: Identification and analysis of key genes in osteosarcoma using bioinformatics. Oncol Lett. 15:2789–2794. 2018.PubMed/NCBI
7	Liu Y, Sun W, Ma X, Hao Y, Liu G, Hu X, Shang H, Wu P, Zhao Z and Liu W: Logistic regression analysis for the identification of the metastasis-associated signaling pathways of osteosarcoma. Int J Mol Med. 41:1233–1244. 2018.PubMed/NCBI
8	Miao J, Wu S, Peng Z, Tania M and Zhang C: MicroRNAs in osteosarcoma: Diagnostic and therapeutic aspects. Tumour Biol. 34:2093–2098. 2013. View Article : Google Scholar : PubMed/NCBI
9	Xu JQ, Zhang WB, Wan R and Yang YQ: MicroRNA-32 inhibits osteosarcoma cell proliferation and invasion by targeting Sox9. Tumour Biol. 35:9847–9853. 2014. View Article : Google Scholar : PubMed/NCBI
10	Yan K, Gao J, Yang T, Ma Q, Qiu X, Fan Q and Ma B: MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One. 7:e337782012. View Article : Google Scholar : PubMed/NCBI
11	Zhang K, Zhang C, Liu L and Zhou J: A key role of microRNA-29b in suppression of osteosarcoma cell proliferation and migration via modulation of VEGF. Int J Clin Exp Pathol. 7:5701–5708. 2014.PubMed/NCBI
12	Li E, Zhang J, Yuan T and Ma B: MiR-145 inhibits osteosarcoma cells proliferation and invasion by targeting ROCK1. Tumour Biol. 35:7645–7650. 2014. View Article : Google Scholar : PubMed/NCBI
13	Han K, Zhao T, Chen X, Bian N, Yang T, Ma Q, Cai C, Fan Q, Zhou Y and Ma B: microRNA-194 suppresses osteosarcoma cell proliferation and metastasis in vitro and in vivo by targeting CDH2 and IGF1R. Int J Oncol. 45:1437–1449. 2014. View Article : Google Scholar : PubMed/NCBI
14	Pan W, Wang H, Jianwei R and Ye Z: MicroRNA-27a promotes proliferation, migration and invasion by targeting MAP2K4 in human osteosarcoma cells. Cell Physiol Biochem. 33:402–412. 2014. View Article : Google Scholar : PubMed/NCBI
15	Shen L, Chen XD and Zhang YH: MicroRNA-128 promotes proliferation in osteosarcoma cells by downregulating PTEN. Tumour Biol. 35:2069–2074. 2014. View Article : Google Scholar : PubMed/NCBI
16	Su Z, Chen D, Li Y, Zhang E, Yu Z, Chen T, Jiang Z, Ni L, Yang S, Gui Y, et al: microRNA-184 functions as tumor suppressor in renal cell carcinoma. Exp Ther Med. 9:961–966. 2015. View Article : Google Scholar : PubMed/NCBI
17	Wu G, Liu J, Wu Z, Wu X and Yao X: MicroRNA-184 inhibits cell proliferation and metastasis in human colorectal cancer by directly targeting IGF-1R. Oncol Lett. 14:3215–3222. 2017. View Article : Google Scholar : PubMed/NCBI
18	Wang YB, Zhao XH, Li G, Zheng JH and Qiu W: MicroRNA-184 inhibits proliferation and promotes apoptosis of human colon cancer SW480 and HCT116 cells by downregulating C-MYC and BCL-2. J Cell Biochem. 119:1702–1715. 2018. View Article : Google Scholar : PubMed/NCBI
19	Liang XG, Meng WT, Hu LJ, Li L, Xing H, Xie G, Wang AQ and Jia YQ: MicroRNA-184 modulates human central nervous system lymphoma cells growth and invasion by targeting iASPP. J Cell Biochem. 118:2645–2653. 2017. View Article : Google Scholar : PubMed/NCBI
20	Gao B, Gao K, Li L, Huang Z and Lin L: miR-184 functions as an oncogenic regulator in hepatocellular carcinoma (HCC). Biomed Pharmacother. 68:143–148. 2014. View Article : Google Scholar : PubMed/NCBI
21	Yin GR, Wang Q, Zhang XB and Wang SJ: Regulatory role of microRNA184 in osteosarcoma cells. Genet Mol Res. 14:14246–14252. 2015. View Article : Google Scholar : PubMed/NCBI
22	Rapp J, Jaromi L, Kvell K, Miskei G and Pongracz JE: WNT signaling-lung cancer is no exception. Respir Res. 18:1672017. View Article : Google Scholar : PubMed/NCBI
23	Bryja V, Gradl D, Schambony A, Arenas E and Schulte G: Beta-arrestin is a necessary component of Wnt/beta-catenin signaling in vitro and in vivo. Proc Natl Acad Sci USA. 104:6690–6695. 2007. View Article : Google Scholar : PubMed/NCBI
24	Seki Y, Yamamoto H, Ngan CY, Yasui M, Tomita N, Kitani K, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, et al: Construction of a novel DNA decoy that inhibits the oncogenic beta-catenin/T-cell factor pathway. Mol Cancer Ther. 5:985–994. 2006. View Article : Google Scholar : PubMed/NCBI
25	Lustig B and Behrens J: The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 129:199–221. 2003.PubMed/NCBI
26	Rubin EM, Guo Y, Tu K, Xie J, Zi X and Hoang BH: Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol Cancer Ther. 9:731–741. 2010. View Article : Google Scholar : PubMed/NCBI
27	An JH, Yang JY, Ahn BY, Cho SW, Jung JY, Cho HY, Cho YM, Kim SW, Park KS, Kim SY, et al: Enhanced mitochondrial biogenesis contributes to Wnt induced osteoblastic differentiation of C3H10T1/2 cells. Bone. 47:140–150. 2010. View Article : Google Scholar : PubMed/NCBI
28	Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G and Cleton-Jansen AM: Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol. 220:24–33. 2010. View Article : Google Scholar : PubMed/NCBI
29	Sun X, He Y, Huang C, Ma TT and Li J: Distinctive microRNA signature associated of neoplasms with the Wnt/β-catenin signaling pathway. Cell Signal. 25:2805–2811. 2013. View Article : Google Scholar : PubMed/NCBI
30	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
31	Euhus DM, Hudd C, LaRegina MC and Johnson FE: Tumor measurement in the nude mouse. J Surg Oncol. 31:229–234. 1986. View Article : Google Scholar : PubMed/NCBI
32	Lindsey BA, Markel JE and Kleinerman ES: Osteosarcoma overview. Rheumatol Ther. 4:25–43. 2017. View Article : Google Scholar : PubMed/NCBI
33	Durfee RA, Mohammed M and Luu HH: Review of osteosarcoma and current management. Rheumatol Ther. 3:221–243. 2016. View Article : Google Scholar : PubMed/NCBI
34	Zhang J, Yan YG, Wang C, Zhang SJ, Yu XH and Wang WJ: MicroRNAs in osteosarcoma. Clin Chim Acta. 444:9–17. 2015. View Article : Google Scholar : PubMed/NCBI
35	Yang J and Zhang W: New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 25:398–406. 2013. View Article : Google Scholar : PubMed/NCBI
36	Lauvrak SU, Munthe E, Kresse SH, Stratford EW, Namløs HM, Meza-Zepeda LA and Myklebost O: Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes. Br J Cancer. 109:2228–2236. 2013. View Article : Google Scholar : PubMed/NCBI
37	Lin BC, Huang D, Yu CQ, Mou Y, Liu YH, Zhang DW and Shi FJ: MicroRNA-184 modulates doxorubicin resistance in osteosarcoma cells by targeting BCL2L1. Med Sci Monit. 22:1761–1765. 2016. View Article : Google Scholar : PubMed/NCBI
38	Zhang X, Ding H, Han Y, Sun D, Wang H and Zhai XU: The significance of microRNA-184 on JAK2/STAT3 signaling pathway in the formation mechanism of glioblastoma. Oncol Lett. 10:3510–3514. 2015. View Article : Google Scholar : PubMed/NCBI
39	Ueno K, Hirata H, Hinoda Y and Dahiya R: Frizzled homolog proteins, microRNAs and Wnt signaling in cancer. Int J Cancer. 132:1731–1740. 2013. View Article : Google Scholar : PubMed/NCBI
40	Schepeler T: Emerging roles of microRNAs in the Wnt signaling network. Crit Rev Oncog. 18:357–371. 2013. View Article : Google Scholar : PubMed/NCBI
41	Li H, Xiang H, Ge W, Wang H, Wang T and Xiong M: Expression and functional perspectives of miR-184 in pancreatic ductal adenocarcinoma. Int J Clin Exp Pathol. 8:12313–12318. 2015.PubMed/NCBI
42	Feng R and Dong L: Inhibitory effect of miR-184 on the potential of proliferation and invasion in human glioma and breast cancer cells in vitro. Int J Clin Exp Pathol. 8:9376–9382. 2015.PubMed/NCBI